1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
698B7E72B69521DE400258C130022900D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-launching-new-oncology-products-in-competitive-markets-preparing-market-constituents-understanding-efficacy-safety-dimensions?opendocument
18
19opendocument
2018.97.9.169
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Product Launch » Product Launch Excellence

Launching New Oncology Products in Competitive Markets: Preparing Market Constituents and Understanding Efficacy and Safety Dimensions

ID: 5849


Features:

16 Info Graphics

13 Data Graphics

190+ Metrics

2 Narratives


Pages/Slides: 37


Published: 2025


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Launching New Oncology Products in Competitive Markets: Preparing Market Constituents and Understanding Efficacy and Safety Dimensions”

STUDY OVERVIEW

The competitive oncology market is a complex and high-stakes arena that demands precision and strategic foresight for successful product launches. With therapies targeting increasingly crowded indications and stakeholder expectations at an all-time high, oncology leaders face unique challenges that require innovative approaches to navigate effectively.

This Best Practices, LLC research delivers essential insights to help oncology leaders identify and implement strategies that mitigate risks while maximizing the impact of their launch efforts. The study provides oncology-specific benchmarks and insights on preparing market constituents for successful entry, optimizing efficacy and safety dimensions, resource allocation, and addressing key launch risks and pitfalls unique to oncology.

KEY TOPICS

  • Top oncology launch success factors
  • Current and potential risks for oncology product launches
  • The relative value of positioning and differentiation dimensions
  • Resource allocation for oncology product launches
  • The most common failure points with leveraging efficacy and safety

KEY METRICS

  • Critical success factors influencing oncology product launches
  • A proven framework for achieving successful market entry in oncology
  • Crafting effective positioning for new oncology products
  • Evaluating the impact of product traits across key positioning categories with external stakeholders
  • Most impactful efficacy dimensions for driving oncology launch success
  • Key advancements required to gain physician adoption and payer support
  • Avoiding common pitfalls in efficacy-driven positioning
  • The role of safety considerations in influencing physician adoption of therapies
  • Comparing safety requirements for monotherapy vs combination regimens in oncology
  • Identifying safety-related risks and pitfalls that can undermine launch success
  • Investment benchmarks for achieving successful launch outcomes
  • Strategies for optimizing resource allocation during late-phase development and launch
  • The role of stakeholder education in enabling market entry, capturing share, and driving sustained growth
  • Addressing risks of market-shaping pitfalls and internal failure points that derail launches

SAMPLE KEY FINDINGS

  • Superior Efficacy Drives Oncology Market Success: Superior efficacy remains the top driver for influencing the oncology market at launch, with 75% of experts prioritizing superiority against competitors and 63% highlighting general treatment efficacy. Other critical factors include addressing unmet medical needs (50%) and demonstrating efficacy in halting disease progression (50%), making these essential for securing physician and payer support.

METHODOLOGY

Best Practices engaged 8 Oncology-focused launch leaders from 8 companies in this research through a benchmarking survey instrument and interviews. Benchmark partners work in such functions as Marketing, Commercial, and Product Franchises.

Industries Profiled:
Consulting; Biotech; Biopharmaceutical; Pharmaceutical


Companies Profiled:
Ardelis Health; F1 Oncology; Incyte; Lexicon Pharmaceuticals; Regeneron; Sandoz; Shire; Syros Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.